1 2020 BPCA Stakeholder Post Mtg Assmt Survey

2020 BPCA Stakeholders Meeting Evaluation
OMB # 0925-0648
Expiration Date: 5/2021
Public reporting burden for this collection of information is estimated to average 5-10 minutes per response, including the
time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments
regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this
burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (09250648). Do not return the completed form to this address.

Thank you for attending the 2020 BPCA Stakeholders Meeting! Please take 5-10
minutes to evaluate this meeting. Our goal is to obtain feedback so that we can
improve the next meeting.
Select the primary reasons for your participation in the 2020 BPCA Stakeholders
Meeting.
Interest in the Best Pharmaceuticals for Children Act
Interest in collaborating with the Pediatric Trials Network
Former member of a therapeutic area working group
Other (please specify)

How did you learn about the 2020 BPCA Annual Meeting?
Best Pharmaceuticals for Children Act updates (emails from
bpca@infinityconferences.com)
U.S. Food and Drug Administration updates
Word of mouth
Other (please specify)

Please provide your feedback regarding the virtual format of this meeting.

Please provide your feedback regarding the content of the meeting.

2020 BPCA Stakeholders Meeting Evaluation
MEETING CONTENT
On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the following
sessions:

Triumphs and Trials in Pediatric Therapeutics – Perspectives from the Pediatric
Trials Network and EMMES Data Coordinating Center
(Benjamin/Zimmerman/Anand)
1

2

3

4

5

Additional Comments

Regulatory Considerations for Addressing Needs in Pediatric Therapeutics
(Alexander/Burckart)
1

Additional Comments

2

3

4

5

The COVID-19 Pandemic: Pediatric Therapeutics, Lessons Learned, and Impact on
Future Directions in Pediatrics Research (Hazra)
1

2

3

4

5

4

5

Additional Comments

NICHD Strategic Planning Overview (Cernich)
1

2

3

Additional Comments

Please provide your feedback regarding the roundtable discussion/breakout
sessions on December 15.

2020 BPCA Stakeholders Meeting Evaluation
GENERAL FEEDBACK

On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” what is your
overall rating of the meeting?
1

2

3

4

5

How can we improve the next BPCA Stakeholders Meeting?

What aspects of the 2020 BPCA Stakeholders Meeting were most useful to you?

2020 BPCA Stakeholders Meeting Evaluation
FUTURE ACTIVITIES

If you are not on the BPCA Stakeholders mailing list, would you like to be added?
Yes
No

Would you like to participate in a BPCA Focus Group in 2021?
Yes
No

If yes, please indicate your preferred area of interest.
Advancing Clinical Trial Design
Biomarkers Research
PK Modeling that Informs Dosing
Pediatric-Friendly Formulations
Pharmacoepidemiology Studies
Systems Pharmacology

2020 BPCA Stakeholders Meeting Evaluation
CONTACT DETAILS - OPTIONAL

If you would like a response to your feedback, to join a BPCA working group, or to
be added to the BPCA Stakeholders distribution list, please be sure to include
your contact information below:
Name
Email Address
Phone